.png)
Company Overview
Coologics is a clinical-stage medical device company focused on redefining how vaginal infections are treated. Our mission is to deliver a drug-free, science-driven solution that provides meaningful relief while addressing the underlying biology of infection and inflammation.
Why Coologics?
-
Drug-free and non-hormonal
-
Designed to deliver rapid symptom relief
-
Addresses multiple infection pathways, not just one
-
Designed to preserve the vaginal microbiome
-
Backed by clinical and microbiological research
Vision for Women’s Health
Founder Spotlight
Coologics was founded by Kim Langdon, MD, a female OB/GYN with 19 years of clinical experience. As a physician, she treated thousands of women suffering from recurrent vaginal yeast infections. As a patient herself, she experienced the limitations of existing therapies firsthand, including burning, irritation, and slow symptom resolution.
​
Her clinical perspective was further shaped by a preterm delivery at
31 weeks gestation, reinforcing the strong connection between vaginal infection, inflammation, and broader reproductive health risks. These combined experiences revealed a clear gap in care and a pressing need for better solutions.
The Insight
Heat is a well-established trigger for vaginal yeast infections. When external cooling provided rapid symptom relief for patients who could not tolerate antifungal drugs, a new hypothesis emerged. If controlled cooling could reduce inflammation and reverse infection conditions, it could offer a fundamentally different treatment pathway.
That insight became the foundation of Coologics.
The Technology
Coologics developed a patented, controlled-cooling medical device designed to safely lower vaginal tissue temperature for a defined period. This approach targets multiple biological drivers of infection, including fungal and bacterial activity, inflammation, pH imbalance, and biofilms.
​
Coologics is investigating a multi-faceted, drug-free platform technology designed to explore an alternative to traditional pharmacologic fungistatic or fungicidal approach by targeting the virulence factors that cause the infection.
Clinical Validation
Preliminary published data from an initial pilot study and animal models are informing our ongoing evaluation of the device. Coologics is advancing through FDA-aligned clinical pathways with the goal of developing a novel, non-pharmacological option for yeast infections and fast alleviation of their symptoms.
Vision
Coologics is evaluating the potential of our cooling platform technology to address broader unmet needs in OB/GYN care. We are actively exploring future pipeline applications for vaginal infections, inflammation, and other health conditions.
​
We believe women deserve treatments that work with their biology, not against it.